

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

Mail Stop 4720

December 11, 2015

VIA E-mail Mr. Gregory P. Sargen Executive Vice President and Chief Financial Officer Cambrex Corp. One Meadowlands Plaza East Rutherford, NJ 07073

> Re: Cambrex Corp Form 10-K for Fiscal Year Ended December 31, 2014 Filed February 6, 2015 Form 10-Q for the Quarterly Period Ended September 30, 2015 Filed November 3, 2015 File No. 001-10638

Dear Mr. Sargen:

We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment, we ask you to provide us with information so we may better understand your disclosure.

Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to this comment, we may have additional comments.

Form 10-Q for the quarterly period ended September 30, 2015 Management's Discussion and Analysis Liquidity and Capital Resources, page 26

1. You state on page 26 that the increase in cash provided by operations was partially offset by higher inventory levels. Further, Note 3 to the consolidated financial statements indicates increases in finished goods of \$11.5 million, work in process of \$31.4 million and raw materials of \$2.3 million during the nine months ended September 30, 2015. Please tell us the reasons for these increases in inventory. Also describe for us, as applicable, the reasonably likely expected impact on financial position, results of Mr. Gregory P. Sargen Cambrex Corp. December 11, 2015 Page 2

> operations and liquidity of any known trends, demands, commitments, events or uncertainties related to these increases.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable Exchange Act rules require. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

In responding to our comment, please provide a written statement from the company acknowledging that:

- the company is responsible for the adequacy and accuracy of the disclosure in the filings;
- staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filings; and
- the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

You may contact Senior Staff Accountants Christine Allen Torney at (202) 551-3652 or Mary Mast at (202) 551-3613 with any questions. In this regard, do not hesitate to contact me at (202) 551-3679.

Sincerely,

/s/ Jim B. Rosenberg

Jim B. Rosenberg Senior Assistant Chief Accountant Office of Healthcare and Insurance